Skip to content
Open access

Effect of Adding Esketamine to Patient-Controlled Intravenous Analgesia on Rebound Pain After Interscalene Brachial Plexus Block: A Randomized Controlled Trial

Oct 2026 · Drug Design, Development and Therapy · Vol 20 · 0 citations · 31 references
Medicine

Abstract

Background Rebound pain after peripheral nerve block (PNB) may diminish the analgesic benefits of regional anesthesia. Whether esketamine administered via postoperative patient-controlled intravenous analgesia (PCIA) can prevent rebound pain remains unclear. This study aimed to evaluate the effect of esketamine-containing PCIA on rebound pain after interscalene brachial plexus block in patients undergoing shoulder arthroscopic surgery. Methods 132 patients scheduled for arthroscopic shoulder surgery under general anesthesia combined with interscalene brachial plexus block were randomized 1:1 to receive postoperative PCIA with esketamine (1.25 mg/kg) plus sufentanil (100 μg) and flurbiprofen axetil (100 mg) (ES group, n=66) or sufentanil plus flurbiprofen axetil alone (Control group, n=66). The primary outcome was rebound pain, defined as an increase from well-controlled pain (NRS ≤ 3) to severe pain (NRS ≥ 7), typically after resolution of the nerve block. Secondary outcomes included time to rebound pain, modified pain score, rebound pain duration, analgesic consumption, numerical rating scale (NRS) at 6, 12, 24, and 48 h postoperatively, Quality of Recovery-15 (QoR-15), Richards-Campbell Sleep Questionnaire (RCSQ) sleep quality, and adverse events. Results The incidence of rebound pain did not differ significantly between groups (25.8% vs 39.4%; OR, 0.53; 95% CI, 0.39 to 1.09; P=0.095). Among patients who developed rebound pain, the ES group had a lower modified rebound pain score and shorter pain duration. For other secondary outcomes, patients receiving esketamine had lower NRS pain scores at 12, 24, and 48 h, fewer PCIA demands, less rescue analgesic use, and higher QoR-15 and RCSQ scores (all P<0.05). The incidence of the assessed adverse events did not differ significantly between groups. Conclusion Adding esketamine to postoperative PCIA did not demonstrate a reduction in rebound pain incidence after interscalene brachial plexus block. Exploratory subgroup findings suggested lower rebound pain intensity and duration, while improvements in postoperative analgesia, sleep, and recovery had uncertain clinical relevance. Further multicenter studies are needed to confirm these findings and to evaluate different dosing strategies and routes of administration.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.